ACLA_webbanner_oct23 ACLA_webbanner_oct23

The Hill: Reform the IOAS self-referral exception

ACLA and stakeholders ask Congress to support integrity in the practice of medicine and soften the blow to seniors by narrowing the IOAS exception, saving billions in Medicare and easing the pain of a Medicare Part B spike in premiums to certain seniors.

Read the Article »

ACLA slider ACLA slider

ACLA Annual Meeting

Presentation slides from ACLA’s 20th annual meeting, “Focus on Reimbursement, Regulation and Innovation,” are now available for viewing online.

View the slides »
ACLA_webbanner_june8 ACLA_webbanner_june8


Learn about the benefits of joining the nation’s leading advocacy organization for clinical laboratories.

ACLA_Calendar_Image copy ACLA_Calendar_Image copy

ICD10 Is Coming October 1 – Are You Ready?

The ICD-10 transition will affect every part of your practice. Now is the time to get ready.

Get Ready »
alanslider alanslider

ACLA Warns Against Duplicative LDT Regulation at House Hearing

At a recent Energy and Commerce Health Subcommittee hearing, ACLA President Alan Mertz cautioned that duplicative regulation of LDTs would be harmful to innovation and patient access to diagnostic services.

Read More »
acla banner acla banner

Boston Globe editorial: ‘FDA rules will do more harm’

A new Boston Globe editorial warns against proposed FDA guidance on laboratory developed tests.

Read the Article »
pama slider pama slider

The Protecting Access to Medicare Act of 2014

Big changes are coming to how Medicare pays for clinical lab services – here’s everything your lab needs to know about the new law. 

Learn More »

View all news & updates » Recent News & Updates

View all news & updates »

Policy Issues

  • Reimbursement and Coverage

    Medicare cuts to clinical labs threaten jobs, stifle innovation, and put patient access to vital lab tests at risk.

    Continue Reading »

  • Laboratory Developed Tests

    FDA regulation of laboratory-developed tests (LDTs) is duplicative, outside of FDA jurisdiction, and would negatively impact patient access to vital lab tests.

    Continue Reading »

  • IOAS Exception

    Self-referral leads to over-utilization, mistreated patients, and billions of wasted Medicare dollars. It’s time to close the loophole.

    Continue Reading »

View all policy issues »